| 查看: 190 | 回复: 1 | |||
| 当前主题已经存档。 | |||
[交流]
FDA最新批准新药信息
|
|||
|
Zelapar Orally Disintegrating Tablets Generic Name: selegiline hydrochloride Date of Approval: June 14, 2006 Company: Valeant Pharmaceuticals International Treatment for: Parkinson's Disease -------------------------------------------------------------------------------- The U.S. Food and Drug Administration (FDA) approved Zelapar (selegiline HCl) Orally Disintegrating Tablets, a once-daily adjunct therapy for Parkinson's disease patients being treated with levodopa/carbidopa who exhibit deterioration in the quality of their response to this therapy. Zelapar, a monoamine oxidase-B (MAO-B) inhibitor, is the first Parkinson's disease treatment to use a novel oral delivery system called Zydis(R) Technology, which allows the tablets to dissolve within seconds in the mouth and deliver more active drug at a lower dose. The use of Zelapar as adjunctive therapy to levodopa/carbidopa has been shown to reduce "off" time, on average, by 2.2 hours per day. Levodopa/carbidopa is commonly used early in the treatment of Parkinson's disease, but as the disease progresses it becomes increasingly difficult to adequately control symptoms with this medication. Parkinson's disease patients may endure many hours of "off" time each day in which their symptoms return as a result of levodopa/carbidopa wearing off. Zelapar Clinical Trial Overview The effectiveness of Zelapar as an adjunct to levodopa/carbidopa in the treatment of Parkinson's disease in patients who exhibit deterioration in the quality of their response to this therapy was established in a 12-week multi-center, double-blind, randomized, placebo-controlled, parallel-group study. Patients received either 1.25 mg of the drug or placebo each day for the first six weeks and then 2.5 mg of the drug or placebo once-daily for the following six weeks. Zelapar was shown to significantly reduce "off" time after one week of treatment. At the end of 12 weeks, Zelapar treated patients had, on average, 2.2 hours per day less "off" time compared to baseline, and placebo-treated patients had 0.6 hours per day less "off" time. The observed reduction in "off" time between the two treatment groups compared to baseline was statistically significant (p less than 0.001). The most common adverse events reported by patients treated with Zelapar were comparable to placebo and included nausea (11%), dizziness (11%), pain (8%), headache (7%), insomnia (7%), rhinitis (7%), dyskinesia (6%), skin disorders (6%), stomatitis (5%), back pain (5%) and dyspepsia (5%). About Zelapar MAO inhibitors have been used as an adjunct therapy in Parkinson's disease since the first clinical trials of levodopa therapy in the early 1960s. Selegiline, the active ingredient in Zelapar, is an MAO-B inhibitor that prevents the breakdown of dopamine, the key neurotransmitter in the brain controlling movement. Using an innovative transbuccal drug delivery system called Zydis Technology, Zelapar Orally Disintegrating Tablets dissolve within seconds in the mouth and deliver more active drug at a lower dose. Zelapar is the first Parkinson's disease treatment to use Zydis, and due to its fast-disintegrating technology, Zelapar significantly bypasses the gut and first-pass hepatic metabolism. It is primarily absorbed into the systemic circulation through the oral mucosa, thereby potentially enhancing the therapeutic effect and reducing side effects. About Parkinson's disease Parkinson's disease is a chronic, progressive disorder of the central nervous system that belongs to a group of conditions called motor system disorders. The symptoms of Parkinson's disease appear when approximately 80 percent of neurons in an area of the brain called the substantia nigra become impaired. In the United States, 1.5 million Americans currently have Parkinson's disease. It is estimated that 60,000 new patients are diagnosed each year. While the condition usually develops after the age of 65, 40 percent of people diagnosed are under age 60. Parkinson's disease affects nearly equal numbers of men and women, with no obvious social, ethnic, economic or geographic boundaries. There presently is no cure for the disease, and the cause is unknown. Important Safety Information Zelapar is contraindicated in patients with a known hypersensitivity to any formulation of selegiline or any of the inactive ingredients of Zelapar. Serious, sometimes fatal reactions have been precipitated with the concomitant use of meperidine (e.g., Demerol and other tradenames) and MAO inhibitors including selective MAO-B inhibitors. These reactions have been characterized by coma, severe hypertension or hypotension, severe respiratory depression, convulsions, malignant hyperpyrexia, excitation, peripheral vascular collapse and death. In addition, the combination of MAO inhibitors and dextromethorphan has been reported to cause brief episodes of psychosis or bizarre behavior. Severe toxicity has also been reported in patients receiving the combination of tricyclic antidepressants and conventional selegiline and selective serotonin reuptake inhibitors and conventional selegiline. Zelapar should not be administered along with other selegiline products. Zelapar may potentiate the dopaminergic side effects of levodopa and may cause or worsen preexisting dyskinesia. Decreasing the dose of levodopa may improve this side effect. 5.2 percent of patients discontinued Zelapar therapy due to adverse events (versus one percent with placebo). Zelapar should be used during pregnancy only if the potential benefit to the mother justifies the potential risk to the fetus. |
回复此楼» 猜你喜欢
26年申博——已发SCI6篇
已经有13人回复
-
2026年山东大学海洋学院生物与医药博士招生-李霞课题组
已经有0人回复
-
药物学论文润色/翻译怎么收费?
已经有139人回复
-
博士研究生招生
已经有0人回复
-
碱缸的配制
已经有5人回复
-
新！澳门科技大学诚招2026年秋季药剂学/生物材料方向博士研究生（申请-考核制）
已经有18人回复
-
澳科大药学院诚招2026年秋季纳米医学/生物材料博士研究生
已经有16人回复
-
医药口服制剂辅料应用
已经有0人回复
-
全新推出Tguide®靶向递送方案，突破99% T细胞转染效率
已经有1人回复
-
Mal-LN29-LNP-mRNA 试剂盒：自带Mal基团，一盒实现抗体筛选与体内靶向验证
已经有0人回复
2楼2006-06-19 20:59:10